Lyell Immunopharma (NASDAQ:LYEL) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Lyell Immunopharma has been downgraded from a "hold" to a "strong sell" rating by Wall Street Zen as of Saturday.
• HC Wainwright maintained a "neutral" rating with a price target of $10.00 on the company's shares, reflecting a cautious outlook.
• The company reported a quarterly EPS of ($2.89), surpassing expectations of ($3.80), despite significant financial challenges including a negative net margin of over 552,000%.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "strong sell" rating in a note issued to investors on Saturday.

Separately, HC Wainwright reissued a "neutral" rating and issued a $10.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, June 24th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lyell Immunopharma currently has an average rating of "Reduce" and an average price target of $15.00.

Lyell Immunopharma Trading Down 1.7%

LYEL traded down $0.18 on Friday, reaching $10.65. The stock had a trading volume of 15,603 shares, compared to its average volume of 70,988. Lyell Immunopharma has a fifty-two week low of $7.65 and a fifty-two week high of $32.40. The firm has a 50-day moving average of $10.25 and a 200-day moving average of $10.36. The company has a market capitalization of $204.59 million, a price-to-earnings ratio of -0.44 and a beta of -0.19.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.80) by $0.91. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%. Sell-side analysts anticipate that Lyell Immunopharma will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $94,000. Bridgeway Capital Management LLC acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $159,000. Walleye Capital LLC acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $258,000. Orbimed Advisors LLC acquired a new position in Lyell Immunopharma in the second quarter valued at approximately $457,000. Finally, Graham Capital Management L.P. acquired a new position in Lyell Immunopharma in the fourth quarter valued at approximately $33,000. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.